GWS
ATNM icon

Glassman Wealth Services’s Actinium Pharmaceuticals ATNM Stock Holding History

Glassman Wealth Services’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed – – 1663
2022
Q1 		$0 Buy
+1
New +$5 ﹤0.01% 1631
2021
Q4 		– Sell
-200
Closed -$2K – 1630
2021
Q3 		$2K Buy
+200
New +$1.39K ﹤0.01% 1133

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Glassman Wealth Services's ATNM Position: Q2 2022 in Review

Glassman Wealth Services sold out of Actinium Pharmaceuticals (ATNM) in Q2 2022, closing a stake of 1 share.

Glassman Wealth Services first reported a position in ATNM in Q3 2021 and held it in 2 quarters. The position peaked at $2K in Q3 2021. 50 funds tracked by Wall St. Rank hold ATNM as of Q2 2022.

  • Glassman Wealth Services reported no remaining Actinium Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 1 Actinium Pharmaceuticals share in Q2 2022.
  • Glassman Wealth Services first reported a position in Actinium Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Glassman Wealth Services's Actinium Pharmaceuticals position peaked at $2K in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2022.

Based on Glassman Wealth Services's 13F filing for Q2 2022, filed 4 Aug 2022.